智通财经APP讯，派格生物医药-B(02565)发布公告，邹醒龙先生(邹先生)已辞任本公司联席公司秘书(联席公司秘书); 香港联合交易所有限公司证券上市规则第 3.05条项下的本公司授权代表(授权代表); 及根据香港法例第622章公司条例第16部代表本公司于香港接收法律程序文件及通知的代表(法律程序代理人)， 自 2026年4月1日起生效。
自邹先生辞任联席公司秘书、授权代表及法律程序代理人后，郭恩廷女士(郭女士)已获委任为联席公司秘书、授权代表及法律程序代理人，自2026年4月1日起生效。黄一峰先生(黄先生)将继续担任另一名联席公司秘书。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.